News

Scientists from The University of Texas at Austin report in the journal Science that they have developed a new strategy to protect honey bees from a deadly trend known as colony collapse: genetically engineered strains of bacteria.

How does a poor kid from tiny Alice, Texas grow up, go to a top research university, patiently pursue a new treatment for cancer that all the experts call crazy, and end up leading a revolution in cancer therapeutics that has already saved countless lives? Oh, and somehow manage to play harmonica with Willie Nelson and win a Nobel Prize too?

We know absolutely nothing about roughly 80 percent of the different types of life on Earth. Biologist David Hillis aims to discover all those missing species—by some estimates 5 to 10 million—possibly in the next few decades. Sound impossible? He shares his vision for how this would work in this first episode of our new miniseries, The Next 50 Years.

In this episode, producer and host Marc Airhart chats with senior editor Christine Sinatra about how the podcast has changed over the last few years (we're now in our fifth year of production – yay!) and where we're going in the future. We also share some exciting news: we're kicking off a new miniseries called The Next 50 Years. The first episode drops in January 2020. Stay tuned!

Nancy Moran, an evolutionary biologist at UT Austin, has built a career on groundbreaking findings about symbiotic relationships between insects and their internal bacteria. Among her many honors and awards, she is a National Academy of Sciences member, an American Association for the Advancement of Science fellow and a MacArthur "Genius" fellow. She was recently profiled in the journal Science.

In a sign of the highly competitive environment for top talent in the field of artificial intelligence (AI), the Sony Corporation this week tapped Peter Stone, a faculty member in the College of Natural Sciences at The University of Texas at Austin, to lead the newly established Sony AI in the United States.

A widely used class of chemotherapy drugs, called topoisomerase inhibitors, come with some serious downsides: bone marrow damage, reduced blood cell production, diarrhea and heart damage. And some cancers can quickly develop resistance. A new discovery about a second class of drugs might lead to combination therapies that are just as effective, but with fewer downsides.

The American Mathematical Society has named Thomas Chen, chair of the Department of Mathematics at The University of Texas at Austin, as one of 52 Fellows of the AMS for 2020. The Fellows of the AMS designation recognizes members who have made outstanding contributions to the creation, exposition, advancement, communication and utilization of mathematics.

A tech startup that spun out of The University of Texas at Austin, Lantha Inc., has successfully completed its first round of venture capital investments, securing $2.6 million from the GOOSE Society of Texas and other investors. The company is commercializing a novel chemical sensor invented at UT Austin that holds promise to dramatically lower costs and return faster results compared with other analytical tools. The innovation could have applications as diverse as the detection of chemical isotopes, quality control testing of feedstocks in manufacturing computer chips and pharmaceuticals, and detecting contamination in drinking water.

Researchers at The University of Texas at Austin and Baylor College of Medicine have developed a new preoperative test for thyroid cancer that is faster and about two-thirds more accurate than the diagnostic tests doctors use today. Although more validation will be necessary before it can be used clinically, the new metabolic thyroid test shows promise for preventing thousands of unnecessary thyroid removals each year, such as the partial removal UT Austin grad student Amanda Helms had due to an inconclusive test.